
UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression
Our integrative model aims to bridge the biomedical-psychedelic divide to offer a feasible, flexible, and standardized approach to ketamine for TRD. Our learnings from developing and implementing this psychedelic-inspired model for severe, real-world patients in two academic hospitals may offer valuable insights for the ongoing roll-out of a range of psychedelic therapies.
Single-dose psilocybin for a treatment-resistant episode of major depression
In ... participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly ... over a period of 3 weeks.
COMPASS pathways announces phase 3 pivotal program design for COMP360 in treatment resistant depression
COMPASS’ program will be the first ever Phase 3 program of psilocybin therapy.